Amphion Innovations : Directors' Dealings Directors Receive Shares in Lieu of Fees

Amphion Innovations plc

Directors' Dealings
Directors Receive Shares in Lieu of Fees

London and New York, 7 January 2016 -Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that the Company has today issued 291,806 ordinary shares in the Company ('New Ordinary Shares'), representing 0.15% of the enlarged issued share capital, to certain of its Board members in lieu of their directors' fees for the fourth quarter of 2015 and the first quarter of 2016, priced at 3.375 pence, being the average of the closing mid-market price for the five days leading up to the market close on 31 December 2015. Following this issue, the directors' shareholdings in the Company are as follows:

Director	Number of New Ordinary Shares	Total Shareholding	Percentage of voting rights
Miroslaw Izienicki	198,056	601,489	0.305%
Gerard Moufflet	93,750	1,273,958	0.645%

Admission of the 291,806 New Ordinary Shares, ranking pari passu with the existing ordinary shares, to trading on AIM is expected on 12 January 2016. Following the issue and allotment of the New Ordinary Shares, the total issued share capital of the Company will increase to 197,511,229 ordinary shares with each share holding one voting right.

For further information please contact

Amphion InnovationsCharlie Morgan
[phone]

Yellow Jersey PR
Charles Goodwin / Dominic Barretto
[phone]

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
[phone]

Northland Capital Partners Limited (Joint Corporate Broker)Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Mark Treharne (Corporate Broking)
[phone]

Plumtree Capital Limited (Financial Adviser)Stephen Austin
[phone]
[phone]

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.